The Biostatistics Core (BC) provides expertise in biostatistics, clinical trials, and experimental design, as well as supporting electronic data management for clinical research. Scientific consultation is provided by faculty statisticians who collaborate in the development of pilot projects, grant proposals and clinical protocols. The BC statisticians help design research studies, and conduct interim and final data analyses. Core services include the development of case-report forms, databases and data entry tools to initiate clinical protocols, as well as access to clinical research and cancer registry data repositories for retrospective research. The Core provides expertise and access to a variety of technologies, including modern statistical computing environments such as SAS, JMP, Splus, and R;specialized statistical computing tools for microarrays, genetic linkage and association studies, and pharmacokinetics;tools to implement scannable forms and electronic data capture;web portals for data entry and study monitoring;and a centralized MS SQL-server database for clinical research. Service to the institution includes statistical review of cancer-related clinical research protocols. The core is directed by Jeffrey Longmate, PhD, Director of the Department of Biostatistics. Co-Director is Joyce Niland, PhD, Director of the Clinical Protocol Management Core. The staff of the BC includes a large part of the department, and the BC enables their participation in Cancer Centerrelated pilot projects and proposals, which may later develop into externally funded projects. The BC is directly involved in Cancer Center research from the inception of a research idea to the publication of results. The BC focuses heavily on clinical research, but also supports basic and translational research, as well as supporting several other cores. The BC collaborates continually with the Biomedical Informatics Core to operate and further develop the MIDAS clinical research database, and regularly collaborates with members of the Clinical Protocol Management Core to implement City of Hope-conducted or coordinated clinical protocols. In 2005, the BC was used by 80 CC members from all Programs, and logged 204 projects, including 21 grants naming BC personnel (7 multi-project grants), and 32 clinical protocols newly opened with BC collaboration. Annual budget for the core is $2,651,640, with 62% from the institution, 34% other sources, and 4% ($100,100) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-27
Application #
8182257
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
27
Fiscal Year
2010
Total Cost
$139,049
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Wu, Chenkai; Ashing, Kimlin Tam; Jones, Veronica C et al. (2018) The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. J Behav Med 41:52-61
Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Paz, Helicia; Joo, Eun Ji; Chou, Chih-Hsing et al. (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17:235-245
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141

Showing the most recent 10 out of 1396 publications